EverImmune develops Oncobax®, a series of live biotherapeutic products that utilize specific strains of bacteria, such as _Akkermansia muciniphila_, to enhance the efficacy of immunotherapy in patients with non-small cell lung cancer. The company aims to improve treatment responses in patients who have previously shown resistance to immunotherapy through clinical trials involving oral administration of these microbiome-based therapies.
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Immunotherapy resistance in non-small cell lung cancer (NSCLC) patients poses a significant challenge, limiting the effectiveness of treatment and impacting patient outcomes. Many patients do not respond to immunotherapy, necessitating alternative or adjunctive therapeutic strategies.
Solution
EverImmune is developing Oncobax®, a series of live biotherapeutic products (LBPs) designed to enhance the efficacy of immunotherapy in NSCLC patients. These microbiome-based therapies utilize specific bacterial strains, including a proprietary strain of _Akkermansia muciniphila_ (Oncobax® AM), to modulate the gut microbiome and improve the patient's response to immunotherapy. Oncobax® is administered orally as an adjuvant to cancer immunotherapies, aiming to convert negative responses to immunotherapy into positive ones. The company employs complementary platforms to characterize Oncobax®, including fecal microbiota transplantation (FMT), single bacterial strains, and bacterial consortia.
Target Audience
The primary target audience includes patients with non-small cell lung cancer who have developed resistance to immunotherapy, as well as oncologists and clinical researchers seeking to improve treatment outcomes.
Features
- Utilizes specific strains of bacteria, such as _Akkermansia muciniphila_, to modulate the gut microbiome.
- Designed as an oral adjuvant to cancer immunotherapies.
- Undergoing clinical trials involving patients with NSCLC resistant to immunotherapy.
- Employs complementary platforms to characterize Oncobax®, including FMT, single bacterial strains, and bacterial consortia.